Updates on the genetic characterization of vitiligo
Abstract
Summary:
Vitiligo is an autoimmune skin disorder in which autoimmune-mediated destruction of melanocytes caused depigmentation of skin patches. The complex genetics of vitiligo involves multiple susceptibility loci, genetic heterogeneity and incomplete penetrance with gene-gene and gene-environment interactions. In order to clarify the genetic factors, two different principal approaches have applied for the identification of genomic regions or candidate genes that mediate susceptibility to vitiligo. First approach is the genome-wide linkage analyses, which is conducted by scanning of entire human genome for genomic regions that are linked to the development of vitiligo. The other approach is functional candidate gene association (FCGA) analyses that detect specific candidate genes, which are expected to involve in disease on the basis of their priori biological functions. Genomic-wide scans have provided a strong support for vitiligo susceptibility genes on chromosomes 4q13-q21, 1p31, 7q22, 8p12 and 17p13, while loci of interest at 6p, 6q, 14q, 9q, 13q, 19p and 22q required further follow-up. Whereas, FCGA studies have identified some candidate genes which are associated with vitiligo, such as HLA, AIRE, VIT1, CAT, FOXD3, ESR1, COMT, PTPN22, NALP1, PDGFRA, MYG1, MITF, CD117, XBP1, FAS, COX2, EDN1 and ACE, but few of them reports now appear to be false-positive. This review will provides an update on genetics of vitiligo based on the identification of novel candidate genes that represent, in my opinion as optimal utility for future therapeutic targets in the pathogenesis of vitiligo.
Keywords: Vitiligo, genetics, novel candidate genes, melonocytes, genome.
Abbreviations:
HLAÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Human leukocyte antigen
CTLA-4Â Â Â Â Â Â Â Â Cytotoxic T lymphocyte-associated antigen 4
ACEÂ Â Â Â Â Â Â Â Â Â Â Â Â Angiotensin-converting enzyme
CAT Â Â Â Â Â Â Â Â Â Â Â Â Â Catalase
PDGFRA Â Â Â Â Â Â Â platelet-derived growth factor receptor,
alpha polypeptide
PTPN22Â Â Â Â Â Â Â Â Protein tyrosine phosphatase, non-receptor
type 22 (lymphoid)
MYG1 Â Â Â Â Â Â Â Â Â Â Melanocyte proliferating gene 1
MITF Â Â Â Â Â Â Â Â Â Â Â Â Microphthalmia- associated transcription
factor
CD117Â Â Â Â Â Â Â Â Â Â Â Cluster of differentiation 117
ESR 1 Â Â Â Â Â Â Â Â Â Â Â Estrogen receptor 1
FOXD3Â Â Â Â Â Â Â Â Â Â Forkhead box D3
AIRE Â Â Â Â Â Â Â Â Â Â Â Â Â The autoimmune regulator
COMT Â Â Â Â Â Â Â Â Â Â Catechol O-methyl transferase
XBP1Â Â Â Â Â Â Â Â Â Â Â Â Â Â X box binding protein 1
EDN1 Â Â Â Â Â Â Â Â Â Â Â Â Â Endothelin-1
COX2 Â Â Â Â Â Â Â Â Â Â Â Â Cyclooxygenase-2
VIT1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vitiligo-associated protein 1
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).